A GlaxoSmithKline (NYSE: GSK) combination therapy for advanced melanoma patients could be a step closer to saving lives. That’s the hope, anyway, after the U.S. Food and Drug Administration granted priority status to two already-approved drugs: Tafinlar, also known as dabrafenib, and Mekinist, or trametinib. GSK believes that the drugs can have a longer lasting effect when combined.
Help employers find you! Check out all the jobs and post your resume.
